Treatment of patients with malignant lymphoma with Mini-BEAM reduces the yield of CD34
؉ peripheral blood stem cells
It is currently unclear whether or not patients with malignant lymphoma who relapse after achieving a complete remission benefit from reinduction chemotherapy prior to mobilization of peripheral blood stem cells (PBSC) and high-dose chemotherapy (HDC). Previous phase II studies in patients with Hodgkin's Disease (HD) or non-Hodgkin's lymphoma (NHL) failed to show a survival advantage for patients in first relapse receiving reinduction chemotherapy before mobilization of PBSC compared to patients proceeding directly to mobilization of PBSC without an attempt to induce a second remission. 1,2 However, the numbers of patients in these studies were few and the potential selection biases great. Therefore, a randomized trial was designed to answer this question. A regimen of carmustine, etoposide, cytarabine and melphalan (Mini-BEAM) was selected for the reinduction arm because of proven efficacy as salvage therapy for patients with relapsed or refractory HD prior to HDC with autologous bone marrow (BM) support. 3, 4 At the first sign of relapse one group of patients was Leu9, Becton Dickinson randomized to receive immediate mobilization of PBSC with cyclophosphamide, etoposide and granulocyte colonystimulating factor (CE/G-CSF) followed by HDC with BEAC 1,2 and the other group received induction with Mini-BEAM and were scheduled to receive the same mobilization and HDC regimens. Fifteen patients were enrolled in this study; seven (six with NHL and one with HD) were randomized to receive Mini-BEAM and eight (six with NHL and two with HD) to receive immediate mobilization of PBSC. Seven patients received one (n = 2) or two (n = 5) cycles of Mini-BEAM at the following doses: carmustine 60 mg/m 2 on day 1, etoposide 75 mg/m 2 on days 2-5, cytarabine 100 mg/m 2 /twice a day on days 2-5 and melphalan 30 mg/m 2 on day 6.
3,4 Table 1 shows the yields of CD34 + cells from each group of patients following CE/G-CSF. None of the seven patients receiving Mini-BEAM achieved the target CD34 + cell dose of у2.5 × 10 6 /kg in a median of five aphereses. 5 Four of the seven patients who received Mini-BEAM underwent second attempts to mobilize PBSC (two with CEP/G-GCSF and two with G-CSF alone) with harvesting of a median of 0.15 × 10 6 (range 0.003-0.8) CD34 + cells/kg in a median of four (range 2-8) aphereses. Three of the seven patients who received Mini-BEAM ultimately received HDC with infusion of 1.57, 1.75 and 2.33 × 10 6 CD34 + cells/kg collected with a total of seven, 13 and seven aphereses, respectively. These results suggest that Mini-BEAM induction will preclude HDC and PBSC support with what is generally considered to be adequate CD34 + cell doses in a large fraction of patients with malignant lymphoma.
Two previous studies have demonstrated the feasibility of performing high-dose therapy with BM support after induction with Mini-BEAM in patients with HD. 3, 4 In one study, delayed platelet recovery was observed in patients receiving Mini-BEAM compared to patients not receiving Mini-BEAM before HDC with BM support. 3 In the second study only 60% of patients receiving two cycles of Mini-BEAM ultimately received HDC with BM support with exclusions due predominantly to toxicities and failure to respond. 4 In the later study engraftment parameters following HDC were not reported.
The impact of Mini-BEAM on BM or PBSC harvests has not been previously evaluated but the administration of carmustine or melphalan has been associated with decreased yields of CD34 + cells. 6 Alternative induction regimens not containing carmustine or melphalan may be more reasonable choices for patients scheduled to receive HDC with PBSC support.
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